Business Context and Reporting Period
Mink Therapeutics, Inc. (INKT) filed a Form 8-K Current Report on December 29, 2025. The filing addresses a change in the composition of the Board of Directors.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report regarding corporate governance changes rather than a periodic financial report.
Material Changes
On December 29, 2025, Robert Kadlec, MD, resigned from the Board of Directors and all associated committees, effective immediately. Dr. Kadlec, who joined the Board in October 2024, departed to accept a senior public service role as Assistant Secretary of War for Nuclear Deterrence and Chemical and Biological Defense Policy and Programs within the United States government.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of material risks and contingencies. Management expressed appreciation for Dr. Kadlec's contributions regarding medicine, public health preparedness, and national service.
Key Facts for Investor Verification
- Robert Kadlec, MD, resigned from the Board effective December 29, 2025.
- The resignation was voluntary and linked to a new government appointment.
- Dr. Kadlec served on the Board for approximately two months (October 2024 to December 2025).
- The filing does not disclose any immediate financial impact or replacement for the director.